DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo

ACTAVIS (NYSE: ACT)

295.37 -1.68 (-0.57%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACT $295.37 -0.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $297.77
Previous Close $297.05
Daily Range $293.70 - $298.94
52-Week Range $193.00 - $317.72
Market Cap $78.6B
P/E Ratio -40.03
Dividend (Yield) $0.00 (0.0%)
Volume 2,627,188
Average Daily Volume 3,526,135
Current FY EPS $17.79

Sector

Healthcare

Industry

Drug Makers

ACTAVIS (ACT) Description

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products. Website: http://www.actavis.com/

News & Commentary Rss Feed

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Teva, Actavis, Other Giants Set to Battle for Generics Space

Progress At Synergy Pharmaceuticals, But Not Enough To Really Please Investors

Paratek Pharmaceuticals: The Next Blockbuster Antibiotic At A Third Of The Valuation

J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Pres

J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Press Releases

Today's Stocks Driving Success For The Drugs Industry

Q1 Earnings Season Ramps Up - Earnings Preview

U.S. court weighs whether to let Actavis drop Alzheimer's drug

Andreas Halvorsen Keeps Buying DVA, HLT, ACT

Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog

Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog

See More ACT News...

ACT's Top Competitors

ACT $295.37 (-0.57%)
Current stock: ACT
JNJ $100.21 (0.63%)
Current stock: JNJ
NVS $102.24 (-0.21%)
Current stock: NVS
RHHBY $35.62 (0.51%)
Current stock: RHHBY